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The heritable forms of epidermolysis
bullosa (EB) make up a phenotypically
and genotypically heterogeneous group
of blistering disorders. EB was initially
divided into three broad categories,
namely, simplex (EBS), junctional (JEB),
and dystrophic (DEB), based on the
topographic location of tissue separation
within the dermal-epidermal basement
membrane zone. More recently, Kindler
syndrome, depicting multiple levels of
tissue separation,was added as the fourth
major subtype of EB (Fine et al., 2014).
Subsequently, however, a number of
clinical variants with refined phenotypic
features were noted. The phenotypic
variability encountered in EB was sub-
sequently shown to reflect genotypic
heterogeneity, and the current database
consists of mutations in a total of 19
distinct genes within the EB spectrum
(Lee et al., 2017; Uitto et al., 2017).
We have recently developed a
disease-specific, gene-targeted panel
next-generation sequencing for identi-
fication of pathogenic variants in EB.
This panel covers 21 distinct genes, 18
of them shown to harbor causative
mutations in EB and three of them
involved in differential diagnosis of skin
fragility disorders. We tested this panel
in a group of patients representative of alarge multiethnic cohort of EB patients
in Iran. Most patients had EB of unde-
fined subtype, and in some cases only
archived DNA was available. This
study was approved by the institutional
review board of the Pasteur Institute of
Iran, and all subjects and parents of
underage patients gave written
informed consent to participate in
research and gave permission to publish
their images. DNA was extracted from
peripheral blood samples from patients,
their parents, and other clinically
affected and unaffected family mem-
bers, including siblings (if available),
using a QIAamp DNA Blood Mini Kit
(Qiagen, Valencia, CA) or by salting-out
method. For DNA, target enrichment
was performed using the TruSeq Custom
Amplicon kit (Illumina Inc., San Diego,
CA). DesignStudio (Illumina Inc.) was
used for library design. All exons, at
least 20 base pairs of the intron at each
intron-exon boundary, and up to 50
base pairs of 3’- and 5’-UTRs were tar-
geted. The designed library contained
the genes CD151, CDSN, CHST8,
COL17A1, COL7A1, DSP, DST,
EXPH5, FERMT1, ITGA3, ITGA6,
ITGB4, JUP, KRT5, KRT14, LAMA3,
LAMB3, LAMC2, PKP1, PLEC, and
TGM5, divided into 421 targets covered
by 968 amplicon probes, which weredesigned to cover 99% of targeted ba-
ses. A total of 36,724,892 reads were
aligned to the human genome, with the
mean coverage of the target region
being 424.
A total of 91 probands representing
91 families with a total of 133 affected
individuals were studied; 43% of pa-
tients were female. Patients’ ages at the
time of the study ranged from 4 days to
55 years. Among them, 38 were infants
(<1 year of age), and seven had already
died from complications of the disease
at the time of the study, but DNA was
available for analysis. All patients had a
tentative diagnosis of EB, based on
neonatal blistering and erosions of the
skin and oral mucous membranes,
associated in some cases with aplasia
cutis congenita and developing scarring
alopecia, paronychia, and dental ab-
normalities (see Supplementary
Figure S1 online). Although EB was
suspected based on clinical presenta-
tion, no definitive subclassification
could be made in 87 patients. Among
the families, 79 showed parental con-
sanguinity, accounting for 87% of all
patients. This is significantly higher
than the general rate of consanguinity
in Iran, 39% (Saadat et al., 2004), sug-
gesting that most causative mutations in
these families would be homozygous.
Bioinformatics analysis of the
sequencing results, followed by manual
interrogation of the original binary align-
ment map files with assistance of Inte-
grative Genomics Viewer, version 2.3.93
(Broad Institute, Boston, MA), identified awww.jidonline.org 2649
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Figure 1. Schematic presentation of the protein products of EB-related genes within the cutaneous basement membrane zone, characteristics of the
mutations and the predicted subtypes of EB. (a) The number of causative mutations identified in each gene in the patients in this study are included in
parentheses. Note that CDSN, CHST8, and TGM5 are expressed primarily in the stratum granulosum and stratum corneum and are associated with acral peeling
skin syndrome, which is in the differential diagnosis of EB. (b) Distribution of causative mutations identified in patients with EB. For each gene, the bar graph on
the left displays the breakdown of types of mutations identified, and the bar graph on the right displays the number of novel versus previously reported mutations
in each gene. (c) Diagnosis of EB subtypes in patients included in the panel, using a combination of the types of mutations and consistent phenotypic
characteristics. The top right pie chart displays classification by major types of EB, and the bottom three charts represent the number of patients diagnosed with
subtypes within each major category (EBS, JEB, and DEB, from left to right). DEB, dystrophic epidermolysis bullosa; EB, epidermolysis bullosa; EBS,
epidermolysis bullosa simplex; JEB, junctional epidermolysis bullosa.
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2650number of sequence variants in all 21
genes. After classification of variants and
their confirmation by Sanger sequencing
in each patient and in his/her relatives as
appropriate, 72 pathogenic or likely
pathogenic variants, according to
American College of Medical Genetics
and Genomics criteria (Richards et al.,
2015), were identified in 68 families in
11 distinct genes (Figure 1a,Journal of Investigative Dermatology (2017), VolumSupplementary Table S1 online). Among
these 72 mutations, 35 (48.6%) were
previously unreported to our knowledge,
based on analysis of the EB literature
and the human gene mutation database
(http://www.hgmd.cf.ac.uk). The distribu-
tion of novel versus previously reported
mutations, along with the types of
mutations identified in each gene, is
indicated in Figure 1b. Identification ofe 137mutations in the genes previously associ-
ated with EB, including eight variants of
unknown significance, in combination
with clinical evaluation and segregation
studies, allowed us to predict the
subtypeof EB in76outof 91 families,with
an efficiency of 83.5% (Figure 1b).
In case of EBS, six patients harbored
pathogenic KRT14 mutations. Autosomal
recessive EBS due to homozygous KRT14
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two heterozygous de novo mutations in
autosomal dominant families were
encountered. The phenotype in allKRT14
patientswas characterized by generalized
trauma-induced blistering with minimal
nail dystrophy. Heterozygous pathogenic
variants in the KRT5 gene were identified
in four patients, three of which were
determined to be de novo. In three of
these patients, the identified variants in
KRT5 were previously associated with
EBS, and when combined with a pheno-
type of generalized blistering and moder-
ate nail dystrophywithout extracutaneous
findings, a diagnosis of EBS generalized
severewasmade. The fourth patient had a
phenotype of blistering along with a
reticulated pattern of hyperpigmented
macules and patches. The variant,
c.1649delG inKRT5, has previously been
associated with EBS with mottled
pigmentation. This variant has addition-
ally been associated with EBS with
migratory circinate erythema (Gu et al.,
2003), but such a phenotype was not
present in our patient. Combining the
patient’s phenotype with the genetic
findings, a final diagnosis of EBS with
mottled pigmentation was made. Two of
the three patients with de novo KRT5
mutations were born to consanguineous
parents.
Mutations in other EBS-related genes
were also found in EXPH5 (two families),
TGM5 (one family), and PLEC (three
families). The mutation in TGM5 was
found in a patient with mild blistering of
the hands, consistent with a diagnosis of
acral peeling skin syndrome. In three
families, PLEC mutations were noted,
and in two of them, examination of the
probands at the ages of 8 and 6 years,
respectively, showed evidence of mus-
cle weakness of the upper extremities,
consistent with EBS with muscular dys-
trophy. In another family with PLEC
mutations, the proband was only 28
days old, apparently with no evidence of
muscle weakness. Given the strong as-
sociation between PLEC mutations and
muscular dystrophy, as well as reports of
delayed presentation of the muscle
findings as late as the fourth decade of
life (Pulkkinen et al., 1996), the patient
was considered to have EBS with
muscular dystrophy and was referred for
additional workup.
Out of 32 patients with JEB, 15 patients
had a diagnosis of generalized severesubtype, based on homozygous loss-of-
function mutations either in LAMA3,
LAMB3, or LAMC2, which encode the
subunits of laminin 332. In fact, five of
these patients had died before 1 year of
age. Seventeen patients with JEB general-
ized intermediate were characterized by
mutations in either the corresponding
genes encoding laminin 332 subunit
polypeptides or in COL17A1, most of
them being previously unreported to our
knowledge (Figure 1b).
In patients with DEB, 25 pathogenic/
likely pathogenic mutations were
identified in COL7A1, seven of them
previously unreported (Figure 1b).
Thirteen families were classified as
generalized severe because of homo-
zygous premature termination codon-
causing mutations (five nonsense,
five splicing, and three indel) in
COL7A1. These patients are predicted
to develop severe mutilating scarring
because of extensive skin fibrosis,
frequently associated with development
of aggressive squamous cell carci-
nomas. A milder phenotype, recessive
DEB generalized intermediate, was
predicted in nine patients because of
the presence of missense, indel,
nonsense, or splicing mutations in one
or both COL7A1 alleles. Those patients
with frameshift or nonsense mutations
with an intermediate phenotype are
predicted to show a more severe
phenotype as they age. In three fam-
ilies, the phenotype was classified as
dominant DEB localized, accompanied
by heterozygous de novo COL7A1
mutations. In one family, a large ho-
mozygous deletion mutation in the
FERMT1 gene was noted, consistent
with the diagnosis of Kindler syndrome
(Figure 1b).
Since the development of this panel,
an additional causative gene, KLHL24,
has been identified in EBS (Has, 2017;
He et al., 2016; Lee et al., 2017; Lin
et al., 2016). All causative mutations
identified in this gene have been located
on the initiation codon of translation.
Therefore, in the 15 patients in this panel
in whom no mutations were found,
sequencing of this site on the KLHL24
gene was performed. None of the 15
patients harbored a mutation at this site.
The importance of identifying specific
mutations in families with EB is empha-
sized by several considerations. First, the
information can be used for earlyprognostication of the progression and
the overall outcome of the disease.
Second, identification of the mutant
genes and specific mutations can be
used for prenatal testing and preim-
plantation genetic diagnosis (Pfendner
et al., 2003). Third, knowledge of the
mutations allows screening for hetero-
zygous carriers in large consanguineous
families, with implications for genetic
counseling. Finally, although EB is
currently an intractable disorder, recent
preclinical studies have suggested new
avenues for potential treatment, some of
which are dependent on the knowledge
of the types of mutations (Atanasova
et al., 2017; Woodley et al., 2017).
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The lupus band (LB) of deposited im-
munoglobulins and complement at the
dermoepidermal junction (DEJ) detec-
ted by direct immunofluorescence can
aid to the diagnosis of cutaneous lupus
erythematosus (Burnham et al., 1963;
Harrist and Mihm, 1980). However,
little is known about the pathogenesis.
Nuclear autoantigens from apoptotic
cells may drive the immunological
response in systemic lupus erythema-
tosus, and several antinuclear anti-
bodies are associated with systemic
lupus erythematosus. Assessing
apoptosis at the DEJ and identifying the
antigens in the LB might provide valu-
able insight into the pathogenesis.We retrospectively selected biopsies
from patients collected between 2002
and 2014 in the biobank of the Gro-
ningen Center for Blistering Diseases
with a positive LB on sun-exposed
lesional or nonlesional skin (Harrist
and Mihm, 1980) and clinical features
compatible with cutaneous lupus ery-
thematosus and/or systemic lupus ery-
thematosus (Supplementary Table S1
online).
To investigate apoptotic DNA frag-
ments at the DEJ, the sections were
stained by the deoxynucleotidyl
transferase fluorescein-dUTP nick end
labeling. Sections were double
stained with IgM or IgG and anti-
bodies against the nuclear antigensdsDNA, Ro/SSA (Ro52), La/SSB, U1
RNP, and Smith (Supplementary
Table S2 online). Skin biopsies of
sun-exposed normal skin as well as
skin biopsies of three patients with
pemphigus erythematosus and a
pseudo “LB” were included as control
specimens (Oktarina et al., 2012). In
addition, three randomly selected bi-
opsies were double stained for
deposited IgM together with mono-
clonal antibodies against desmoglein
1, desmoglein 3, type XVII collagen,
type IV collagen, and type VII
collagen.
In 10 of 19 skin biopsies (53%),
deoxynucleotidyl transferase
fluorescein-dUTP nick end labeling
positive cell fragments were found at
the DEJ (Supplementary Table S1). In 9
of 19 skin biopsies (47%), one or more
nuclear antigens were demonstrated at
the DEJ and showed colocalization
